{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T12:40:10Z","timestamp":1766407210354},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Human papilloma virus (HPV) causes multiple anogenital diseases including cervical cancer and is the most common sexually transmitted infection. Healthcare resource utilization (HRU) associated with HPV-related anogenital diseases includes diagnostic and disease specific treatment regimens. A recent study showed disease burden of young women aged 23\u201325\u00a0years, who were the first populations eligible to receive HPV vaccination after its introduction in Germany. Cost for the German statutory health insurance (SHI) due to HPV\u2011related anogenital diseases in this population are unknown. This study aimed at assessing HRU and costs related to HPV-associated anogenital diseases for the Germany SHI.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We used a retrospective, matched cohort design to leverage the prior identified cohort of 23\u201325-year-old women born between 1989\u20131992 diagnosed with HPV-related anogenital disease from the Institute for Applied Health Research Berlin (InGef) Research Database. German SHI claims data from 2012\u20132017 were analyzed. The prior identified cases were matched (direct, without replacement) to women without anogenital diseases (1:10 ratio). HRU and costs for inpatient care, outpatient care, and pharmaceutical during a 3-year observation period were determined for both cases and controls and increments between the groups were assessed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>2,972 women diagnosed with anogenital diseases (cases) who were matched to 29,720 women without anogenital diseases (controls). Cases had more outpatient visits (52.4 visits vs. 39.2 visits) and more cases (45.2% vs. 31.7%) were hospitalized at least once in the 3\u2011year observation period. Most common outpatient procedures performed in cases were conization of the cervix uteri (4.4% cases; <jats:italic>n<\/jats:italic>\u2009&lt;\u20095 controls), followed by other excision and destruction of diseased tissue of the cervix uteri (3.1% in cases; 0.0% in controls). Median difference in total healthcare costs of \u20ac684 (mean difference: \u20ac1,089, 95%CI: \u20ac752\u20131,426) suggest that HPV-related anogenital diseases were responsible for approximately \u20ac3.2\u00a0Million more healthcare costs for the identified cases in the four birth cohorts within the 3\u2011year observation period in the InGef Research Database. Costs were mainly driven by outpatient care (41.6% of total costs).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In Germany, HPV-related anogenital diseases among young women are associated with considerable HRU and financial expenditures, mostly driven by outpatient care.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12913-022-08397-1","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T13:06:11Z","timestamp":1659704771000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Healthcare resource utilization and costs in 23\u201325-year-old women with human papillomavirus (HPV) associated anogenital diseases in Germany \u2013 a retrospective analysis of statutory health insurance claims data"],"prefix":"10.1186","volume":"22","author":[{"given":"Miriam","family":"Reuschenbach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Mihm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regine","family":"W\u00f6lle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim Maren","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Greiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Hampl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,5]]},"reference":[{"key":"8397_CR1","unstructured":"World Health Organization. Human papillomavirus (HPV) and cervical cancer. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/human-papillomavirus-(hpv)-and-cervical-cancer. Accessed 4 Aug 2022."},{"key":"8397_CR2","doi-asserted-by":"publisher","first-page":"100202","DOI":"10.1016\/j.pvr.2020.100202","volume":"10","author":"DG Ferris","year":"2020","unstructured":"Ferris DG, Brown DR, Giuliano AR, Myers E, Joura EA, Garland SM, Kjaer SK, Perez G, Saah A, Luxembourg A, et al. Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial. Papillomavirus Res (Amsterdam, Netherlands). 2020;10:100202.","journal-title":"Papillomavirus Res (Amsterdam, Netherlands)"},{"issue":"7","key":"8397_CR3","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1002\/ijc.24116","volume":"124","author":"H De Vuyst","year":"2009","unstructured":"De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer. 2009;124(7):1626\u201336.","journal-title":"Int J Cancer"},{"issue":"7","key":"8397_CR4","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1056\/NEJM199802123380703","volume":"338","author":"GY Ho","year":"1998","unstructured":"Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338(7):423\u20138.","journal-title":"N Engl J Med"},{"issue":"1","key":"8397_CR5","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s12879-020-05002-w","volume":"20","author":"M Reuschenbach","year":"2020","unstructured":"Reuschenbach M, Mihm S, W\u00f6lle R, Schneider KM, Jacob C, Braun S, Greiner W, Hampl M. Burden of HPV related anogenital diseases in young women in Germany - an analysis of German statutory health insurance claims data from 2012 to 2017. BMC Infect Dis. 2020;20(1):297.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"8397_CR6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/1471-2334-8-76","volume":"8","author":"P Hillemanns","year":"2008","unstructured":"Hillemanns P, Breugelmans JG, Gieseking F, B\u00e9nard S, Lamure E, Littlewood KJ, Petry KU. Estimation of the incidence of genital warts and the cost of illness in Germany: A cross-sectional study. BMC Infect Dis. 2008;8(1):76.","journal-title":"BMC Infect Dis"},{"key":"8397_CR7","first-page":"345","volume":"29","author":"K Petry","year":"2008","unstructured":"Petry K, Breugelmans G, Benard S, Lamure E, Littlewood K, Hillemanns P. Cost of screening and treatment of cervical dyskaryosis in Germany. Eur J Gynaecol Oncol. 2008;29:345\u20139.","journal-title":"Eur J Gynaecol Oncol"},{"issue":"1","key":"8397_CR8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/1471-2334-11-73","volume":"11","author":"M Hampl","year":"2011","unstructured":"Hampl M, Huppertz E, Schulz-Holstege O, Kok P, Schmitter S. Economic burden of vulvar and vaginal intraepithelial neoplasia: retrospective cost study at a German dysplasia centre. BMC Infect Dis. 2011;11(1):73.","journal-title":"BMC Infect Dis"},{"key":"8397_CR9","unstructured":"Gemeinsamer Bundesausschuss. Programm zur Fr\u00fcherkennung von Geb\u00e4rmutterhalskrebs. Available from: https:\/\/www.g-ba.de\/themen\/methodenbewertung\/ambulant\/frueherkennung-krankheiten\/erwachsene\/krebsfrueherkennung\/gebaermutterhalskrebs-screening\/. Accessed 4 Aug 2022."},{"key":"8397_CR10","unstructured":"Gross GE, Werner RN, Becker JC, Brockmeyer NH, Esser S, Hampl M, et al. S2k Leitlinie - HPV-assoziierte L\u00e4sionen der \u00e4u\u00dferen Genitalregion und des Anus \u2013 Genitalwarzen und Krebsvorstufen der Vulva, des Penis und der peri- und intraanalen Haut (AWMF-Registernummer: 082-008). Available from: https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/082-008l_S2k_HPV_assoziierte_anogenitale_L%C3%A4sionen_2017-11-verlaengert.pdf. Accessed 4 Aug 2022."},{"key":"8397_CR11","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). Pr\u00e4vention des Zervixkarzinoms, Langversion 1.1, 2020, AWMF Registernummer: 015\/027OL. Available from: https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/015-027OLl_Praevention_Zervixkarzinom_2020-03-verlaengert.pdf. Accessed 4 Aug 2022."},{"key":"8397_CR12","unstructured":"Diagnosis, Therapy, and Follow-Up Care of Vulvar Cancer and its Precursors. National Guideline of the German Society of Gynecology and Obstetrics (S2k-Level, AWMF Registry No. 015\/059, August 2015). Available from: https:\/\/www.pathologie.de\/?eID=downloadtool&uid=1407. Accessed 4 Aug 2022."},{"key":"8397_CR13","unstructured":"Bundesministerium f\u00fcr Gesundheit. Kennzahlen der Gesetzlichen Krankenversicherung 2008 bis 2021. Kennzahlen und Faustformeln. Available from: https:\/\/www.bundesgesundheitsministerium.de\/fileadmin\/Dateien\/3_Downloads\/Statistiken\/GKV\/Kennzahlen_Daten\/KF2021Bund_Juli_2021.pdf. Accessed 4 Aug 2022."},{"key":"8397_CR14","unstructured":"Statistisches Bundesamt. Ergebnisse der Bev\u00f6lkerungsfortschreibung auf Grundlage des Zensus 2011. Available from: https:\/\/www.destatis.de\/DE\/Themen\/Gesellschaft-Umwelt\/Bevoelkerung\/Bevoelkerungsstand\/Tabellen\/liste-zensus-geschlecht-staatsangehoerigkeit.html. Accessed 4 Aug 2022."},{"key":"8397_CR15","unstructured":"GKV-Spitzenverband. Die gesetzlichen Krankenkassen. Anzahl der Krankenkassen im Zeitablauf \u2013 Konzentrationsprozess durch Fusionen (Angaben am Stichtag 1.1.). Available from: https:\/\/www.gkv-spitzenverband.de\/krankenversicherung\/kv_grundprinzipien\/alle_gesetzlichen_krankenkassen\/alle_gesetzlichen_krankenkassen.jsp. Accessed 4 Aug 2022."},{"key":"8397_CR16","unstructured":"Statistisches Bundesamt. Ergebnisse der Bev\u00f6lkerungsfortschreibung auf Grundlage des Zensus 2011. Available from: https:\/\/www.destatis.de\/DE\/Themen\/Gesellschaft-Umwelt\/Bevoelkerung\/Bevoelkerungsstand\/_inhalt.html. Accessed 4 Aug 2022."},{"issue":"1","key":"8397_CR17","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/pds.3895","volume":"25","author":"F Andersohn","year":"2016","unstructured":"Andersohn F, Walker J. Characteristics and external validity of the German Health Risk Institute (HRI) Database. Pharmacoepidemiol Drug Saf. 2016;25(1):106\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"8397_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.puhe.2022.02.013","volume":"206","author":"M Ludwig","year":"2022","unstructured":"Ludwig M, Enders D, Basedow F, Walker J, Jacob J. Sampling strategy, characteristics and representativeness of the InGef research database. Public Health. 2022;206:57\u201362.","journal-title":"Public Health"},{"key":"8397_CR19","unstructured":"Statistisches Bundesamt. Fortschreibung des Bev\u00f6lkerungsstandes Deutschland - Bev\u00f6lkerung: Deutschland, Stichtag, Altersjahre, Nationalit\u00e4t\/Geschlecht\/Familienstand. Available from: https:\/\/www-genesis.destatis.de\/genesis\/online?operation=abruftabelleBearbeiten&levelindex=2&levelid=1629810259830&auswahloperation=abruftabelleAuspraegungAuswaehlen&auswahlverzeichnis=ordnungsstruktur&auswahlziel=werteabruf&code=12411-0006&auswahltext=&nummer=5&variable=5&name=GES&werteabruf=Werteabruf#abreadcrumb. Accessed 4 Aug 2022."},{"key":"8397_CR20","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte. ICD-10-GM - Versionsverlauf und Bekanntmachungen. Available from: https:\/\/www.dimdi.de\/dynamic\/de\/klassifikationen\/icd\/icd-10-gm\/historie\/versionsverlauf\/. Accessed 4 Aug 2022."},{"key":"8397_CR21","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.pvr.2015.06.003","volume":"1","author":"S Hartwig","year":"2015","unstructured":"Hartwig S, Baldauf J-J, Dominiak-Felden G, Simondon F, Alemany L, de Sanjos\u00e9 S, Castellsagu\u00e9 X. Estimation of the epidemiological burden of HPV-related anogenital cancers, precancerous lesions, and genital warts in women and men in Europe: Potential additional benefit of a nine-valent second generation HPV vaccine compared to first generation HPV vaccines. Papillomavirus Res. 2015;1:90\u2013100.","journal-title":"Papillomavirus Res"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-022-08397-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-022-08397-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-022-08397-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T13:07:40Z","timestamp":1659704860000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-022-08397-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["8397"],"URL":"https:\/\/doi.org\/10.1186\/s12913-022-08397-1","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,5]]},"assertion":[{"value":"24 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. Anonymized SHI data were used for this study. The use of such data is not subject to ethics committee approval in Germany (Good Practice of Secondary Data Analysis (GPS)). All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MR, SM, and RW are full-time employees of MSD Sharp & Dohme GmbH. EG is a full-time employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. KMS and CJ are full-time employees of Xcenda GmbH, acting as contractors of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA for the execution of this study. WG declares no conflict of interest. MH received honoraria as speaker and member of medical advisory boards from MSD Sharp & Dohme GmbH.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1002"}}